You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Clear Cell Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Clear Cell Carcinoma Trial in Houston (Dostarlimab, LB-100)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 26, 2023

Ovarian Clear Cell Carcinoma Trial (Zimberelimab, Metformin Hydrochloride)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • (no location specified)
Feb 25, 2023

Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • +2 more
  • (no location specified)
May 14, 2023

Ovarian Clear Cell Carcinoma Trial (Camrelizumab)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • (no location specified)
Oct 29, 2022

Ovarian Tumors, Endometrial Tumors, Uterine Cervical Tumors Trial (Dostarlimab, Bevacizumab, Doxorubicin)

Not yet recruiting
  • Ovarian Neoplasms
  • +5 more
  • (no location specified)
Sep 3, 2023

Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Gynecologic Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Oct 13, 2022

Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma Trial in London (Savolitinib, MEDI4736, Tremelimumab)

Active, not recruiting
  • Renal Clear Cell Carcinoma
  • Renal Papillary Cell Carcinoma
  • London, United Kingdom
    Thomas Powles
Aug 10, 2022

Moesin Expression in Clear Cell Renal Cell Carcinoma

Completed
  • Renal Cell Carcinoma
  • Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
  • (no location specified)
Sep 20, 2023

Ovarian Clear Cell Carcinoma Trial in Wuhan (Sintilimab, Bevacizumab Biosimilar IBI305)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Wuhan, Hubei, China
    Tongji Hospital of Tongji Medical College, Huazhong University o
Apr 18, 2022

Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • 68Ga-NY104 PET/CT
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 18, 2023

Clear-cell Metastatic Renal Cell Carcinoma Trial in Guangzhou (Drug: Pembrolizumab)

Not yet recruiting
  • Clear-cell Metastatic Renal Cell Carcinoma
  • Drug: Pembrolizumab
  • Guangzhou, Guangdong, China
  • +1 more
Oct 7, 2022

Renal Cell Carcinoma Trial (Sunitinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • (no location specified)
Sep 11, 2023

Metastatic Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)

Not yet recruiting
  • Metastatic Clear Cell Renal Cell Carcinoma
  • 68Ga-NY104 PET/CT
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 18, 2023

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • 68Ga-NY104 PET/CT
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 28, 2023

Renal Cell Carcinoma Trial (HS-10516)

Not yet recruiting
  • Renal Cell Carcinoma
  • (no location specified)
Sep 24, 2023

Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)

Available
  • Clear Cell Renal Cell Carcinoma
  • 89Zr-DFO-girentuximab
  • Los Angeles, California
    UCLA
Oct 12, 2023

ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer Trial (NKT2152, palbociclib, sasanlimab)

Not yet recruiting
  • ccRCC
  • +20 more
  • (no location specified)
Jul 6, 2023

First-line Treatment of Non-clear Renal Cell Carcinoma Trial (Fruquintinib combined with Serplulimab)

Not yet recruiting
  • First-line Treatment of Non-clear Renal Cell Carcinoma
  • Fruquintinib combined with Serplulimab
  • (no location specified)
Apr 16, 2023

Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104)

Completed
  • Clear Cell Renal Cell Carcinoma
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Feb 6, 2023

Carcinoma, Renal Cell Trial (Orellanine)

Not yet recruiting
  • Carcinoma, Renal Cell
  • (no location specified)
Jan 25, 2023

Kidney Cancer, Renal Cell Carcinoma, Clear Cell Carcinoma Trial in Dallas (13C-Glucose, 13C-Acetate, 13C-Lactate)

Recruiting
  • Kidney Cancer
  • +11 more
  • 13C-Glucose
  • +4 more
  • Dallas, Texas
    University of Texas Southwestern Medical Center
Dec 1, 2022

Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer Trial in New Haven (APG-5918)

Recruiting
  • Nasopharyngeal Carcinoma
  • +8 more
  • Springdale, Arkansas
    Highlands Oncology
Nov 11, 2022

Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) Trial run by the National Cancer Institute

Not yet recruiting
  • Advanced Clear Cell Renal Carcinoma (Ccrcc)
  • Papillary Renal Cell Carcinoma (Prcc)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Renal Cell Carcinoma Trial in Guangzhou (Pucotenlimab Combined With Lenvatinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • Pucotenlimab Combined With Lenvatinib
  • Guangzhou, Other (Non U.s.), China
    Sun Yat-sen University Cancer Center
Nov 10, 2023